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ABSTRACT 
 Diagnostic Patterns and Immunohistochemical Stain Usage in Extended Core Prostate 
Biopsies: Comparisons Between Genitourinary and Non-Genitourinary Pathologists 
Anna Plourde MSIV, Zhong Jiang MD, Christopher L. Owens MD 
University of Massachusetts Medical School, Department of Pathology, Worcester, MA 
CONCLUSION 
RESULTS 
A B C 
D E F 
•  Significant differences exist in patterns of diagnostic outcome and IPOX stain usage between 
genitourinary and non-genitourinary pathologists for extended core prostate biopsies in this single 
institution study. 
•  The extreme variability in the range of IPOX stain ordering rates observed in the non-GU 
pathologists as compared to the GU pathologists suggests that there is both over- and 
underutilization of IPOX stains in the non-GU group. 
•  The results suggest the need for guidelines and continuing education focused on this issue to 
standardize practice, an intervention likely to improve quality of diagnoses and to reduce 
unnecessary costs.  
RESULTS (continued) 
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Background: Ancillary immunohistochemical (IPOX) stains are useful in clarifying 
diagnostically challenging pathologic specimens.  In diagnostic workup of prostate 
needle biopsies, stains for basal cells and α-methylacyl coenzyme A racemase (AMACR) 
are routinely used to support or refute the diagnosis of prostate cancer.  Although useful, 
these stains add cost and must be used judiciously.  There is a lack of firm guidelines 
establishing the proper utilization of IPOX studies in prostate pathology. Therefore, 
differences in patterns of stain use and diagnoses may exist, related to expertise of the 
pathologist. 
  
Objectives: The purpose of this study was to compare patterns of diagnoses and IPOX 
stain use in extended core prostate biopsies between genitourinary (GU) and non-
genitourinary (non-GU) pathologists in the University of Massachusetts Medical Center 
Pathology department.  
  
Methods: By computer search of medical records, consecutive extended core prostate 
biopsies (6+ cores) from years 2006-2011 were identified.  Using Current Procedural 
Terminology (CPT) billing data, the number of cores and number of IPOX stains were 
retrieved.  Prostate biopsy diagnoses were recorded. Pathologists who diagnosed prostate 
biopsies meeting computer search criteria were divided into two groups based on 
expertise: genitourinary and non-genitourinary.  Differences in the patterns of IPOX use 
and diagnoses between the two groups were analyzed.  
  
Results: GU pathologists diagnose significantly higher rates of prostate cancer and 
atypical small acinar proliferation and significantly lower rates of high-grade prostatic 
intra-epithelial neoplasia. Both groups order IPOX stains less as the percentage of 
Gleason score 4 disease increases in moderately differentiated cancers and as extent of 
disease increases.  The average rate of IPOX use is not significantly different in the two 
groups. However, GU pathologists order IPOX stains significantly less in cancer cases 
and more in HGPIN cases.  Finally, the variability in rate of IPOX usage is higher in the 
non-GU group.  
 
Conclusion: Significant differences exist in patterns of IPOX usage between GU and 
non-GU pathologists in extended core prostate biopsies in this single institution study. 
Notably, the range of average number of IPOX stains ordered per case was much wider 
for non-GU pathologists, suggesting both over- and underutilization of stains in this 
group.  This suggests the need for guidelines and continuing education focused on this 
issue to standardize practice, an intervention likely to improve quality of diagnoses and to 
reduce unnecessary costs. 
•  GU pathologists diagnose significantly higher rates of prostate cancer and atypical small 
acinar proliferation. 
•  GU pathologists diagnose significantly lower rates of high-grade prostatic intra-epithelial 
neoplasia.   
Diagnosis                                 GU Non-GU p-value 
Benign 591 (42.8%) 535 (47.94%) 0.01 
HGPIN 92 (6.7%) 134 (12.0%) <0.001 
ASAP 93 (6.7%) 48 (4.3%) 0.009 
Cancer 605 (43.8%) 399 (35.8%) <0.001 
Total 1381 1116   
Table 1.  Summary of all cases.  HGPIN = High grade intraepithelial neoplasia.  ASAP = atypical small acinar proliferation 
suspicious but not diagnostic of cancer. 
Table 5.  Rate of IPOX use by extent of disease. 
  Benign HGPIN ASAP Cancer Average IPOX Rate 
Range of IPOX 
Use 
GU 0.41 1.13 2.28 0.79 0.75 0.68-0.86 
Non-GU 0.38 0.71 2.09 1.02 0.72 0.20-2.17 
p-value 0.75 0.03 0.57 0.03 0.67 
•  Both groups of pathologists order IPOX stains less as extent of disease increases. 
Table 6.  Rates of IPOX use by diagnosis, average rate of IPOX ordering, and range of IPOX ordering. 
Figure 1.  Left Image: A relatively small focus of prostate cancer is present in this biopsy (H&E, 200x).  Although the focus 
is small, glomeruloid pattern is present, a microscopic feature that is only present in prostate cancer and absent in all benign 
mimickers.  Right Image: Same focus stained with PIN-4 immunostain shows lack of basal cells and increased AMACR 
expression, confirming the diagnosis of cancer. An expert genitourinary pathologist may be more likely to recognize the 
glomeruloid pattern as pathognomonic for cancer and thus less likely to order ancillary stains in this case. 
 
  Highest Gleason Score of Cancer   
  3+3=6 3+4=7 4+3=7 8,9,10* No Gr PNI Total 
GU 276 (45.6%) 139 (23.0%) 85 (14.1%) 102 (16.9%) 3 (0.5%) 186 (30.7%) 605 
Non-GU 198 (49.6%) 92 (23.1%) 53 (13.28%) 56 (14.0%) 0 121 (30.3%) 399 
p-value 0.22 1 0.78 0.25 0.028 0.94   
Table 2.  Distribution of Gleason grades of cancer cases. * Includes all cases where highest Gleason score recorded was Gleason 
score 8, 9 or 10.  No Gr indicates Gleason score could not be assigned.  PNI = Perineural invasion. 
•  There are no significant differences in the distribution of the Gleason scores or rate of 
perineural invasion in cancer cases between the two groups of pathologists. 
Unilateral Disease Bilateral Disease 
  Focal One Core, non-focal Multiple Cores   Focal Multiple Cores Total 
GU 92 (15.2%) 56 (9.3%) 195 (32.2%)   123 (20.3%) 139 (23.0%) 605 
Non-GU 62 (15.5%) 41 (10.3%) 130 (32.6%)   89 (22.3%) 77 (19.3%) 399 
p-value 0.93 0.59 0.95   0.48 0.18   
Table 3.  Distribution of extent of disease in cancer cases. Unilateral disease, Focal = one positive core 10% or less involvement. 
Unilateral disease, One Core, non-focal  =  One positive core greater than 10% involvement.  Unilateral disease, Multiple Cores = 
Multiple ipsilateral positive cores.  Bilateral Disease, Focal = Bilateral positive cores (One side or both sides with only one positive 
core).  Bilateral Disease, Multiple Cores = Multiple positive cores bilaterally. 
•  There are no significant differences in the distribution of extent of disease in cancer cases 
between the two groups of pathologists. 
  Highest Gleason Score of Cancer 
  3+3=6 3+4=7 4+3=7 8,9,10 No Gr 
GU 1.34 0.35 0.11 0.48 0.93 
Non-GU 1.62 0.58 0.37 0.28 NA 
Table 4. Rate of IPOX usage by tumor Gleason grade.  Rate of IPOX usage = billed IPOX units (88342) / billed biopsy units 
(88305) x 4.  The rate was multiplied by four to correlate with “Triple stains / 12 jar extended core biopsy”. 
•  Both groups of pathologists order IPOX stains less as the percentage of Gleason score 4 
increases in moderately differentiated cancers. 
  Unilateral disease  Bilateral Disease 
  Focal One Core, non-focal Multiple Cores   Focal Multiple Cores 
GU 1.9 0.99 0.69   0.78 0.14 
Non-GU 2.13 0.97 0.91   0.98 0.39 
•  The average rate of IPOX stain ordering is not significantly different between the two groups of 
pathologists. 
•  However, GU pathologists order IPOX stains significantly less in cancer cases and more in 
HGPIN cases. 
•  The range of average number of IPOX stains ordered per case is much wider for non-GU 
pathologists. 
